A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
Disease/Condition: Migraine Headache
Enrollment Opens: 07/21/2021
Enrollment Closes: TBD
This is a study for patients with CHRONIC migraine and patients must have between 4-18 migraine attacks per month and 6 or more migraine days per month. The study is looking at the safety and effectiveness of oral Zavegepant in the prevention of chronic migraine attacks.
Study ID: Biohaven 3500-302
To Enroll: Please call (503) 228-2273 (CARE) to talk with someone about setting up an intake appointment. Or contact http://www.summitresearchnetwork.com for additional informaton.
Posted by: Summit Headlands LLC | http://www.summitresearchnetwork.com